Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN52711596
ISRCTN52711596
Completed
未知

A prospective randomised trial of adjuvant chemotherapy in node positive early stage carcinoma of the cervix

Cancer Research UK (CRUK) (UK)0 sites0 target enrollmentJuly 1, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCervix cancerCancerMalignant neoplasm of cervix uteri

Overview

Phase
未知
Intervention
Not specified
Conditions
Cervix cancer
Sponsor
Cancer Research UK (CRUK) (UK)
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2001
End Date
February 28, 1996
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Cancer Research UK (CRUK) (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Histologically proven invasive adeno or squamous cell carcinoma of the cervix
  • •2\. Histologically proven pelvic lymph node involvement
  • •3\. Stage Ib or IIa disease
  • •4\. Fit to receive either treatment arm
  • •5\. Adequate renal hepatic and haematological function
  • •6\. Adequate pulmonary function
  • •7\. Patients with a probability of \<0\.2 of not developing severe encephalopathy with ifosfamide/mensa treatment are excluded
  • •8\. No second primary tumour other than basal cell carcinoma of the skin
  • •9\. No other serious medical or psychological condition precluding treatment

Exclusion Criteria

  • •Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A prospective randomized study of adjuvant chemotherapy with navelbine and cisplatin in completely resected non small cell lung cancer
ISRCTN95053737Pierre Fabre Oncologie (France)840
Active, not recruiting
Not Applicable
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high risk of relapse based on the Pervenio? Lung RS AssayCompletely resected stage I non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-001494-24-ESEncore Clinical, Inc1,050
Active, not recruiting
Phase 1
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029517Term: Non-small cell lung cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-001494-24-FRIFCT1,050
Recruiting
Phase 1
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lungcancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code: 10025050Term: Lung cancer non-small cell stage I Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025051Term: Lung cancer non-small cell stage II Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025044Term: Lung cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2024-511185-37-00Razor Genomics Inc.915
Active, not recruiting
Phase 1
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-001494-24-DERazor Genomics, Inc.1,050